A Roche Sequencing Study Reveals New Insights in Drug Resistance and Tropism Associated with the New HIV Integrase and Entry Inhibitor Therapy Classes

BRANFORD, Conn. & MONTREAL--(BUSINESS WIRE)--New data from two studies, presented last week at the 16th Conference on Retroviruses and Opportunistic Infections (CROI) in Montreal, Canada demonstrate that ultra-deep sequencing with the Genome Sequencer FLX System from 454 Life Sciences, in combination with traditional methods, may provide a deeper understanding of baseline viral resistance and tropism, leading to potential improvements in the way new drugs may be selected for HIV patients in the future. Effective drug selection for combination therapy is critical to ensure patients obtain optimal, long term suppression of HIV and prevent progression to AIDS.

Back to news